Ryan Charles S.
SEC insider (Form 3/4/5 filer). CIK 0001624830. Director at Polaryx Therapeutics, Inc. (PLYX) and 1 other issuer. 3 reported Form 4/5 transactions since Sep 2024; latest on Jan 23, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Ryan Charles S. has filed insider reports for
- Polaryx Therapeutics, Inc. (PLYX): Director
- Quince Therapeutics, Inc. (QNCX): Officer, President
Ryan Charles S.
CIK: 0001624830
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jan 23, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
200K shares- - Jun 18, 2025QNCX
Quince Therapeutics, Inc.
AwardDirect7.5K shares at avg. $1.20$9K - Jan 28, 2025QNCX
Quince Therapeutics, Inc.
AwardDirectEmployee Stock Option (right to buy)
300K shares-
1-3 of 3 transactions